Imclone llc

The cetuximab–IRDye800 was produced under cGMP conditions at the University of Alabama (UAB) Vector Production Facility before shipment to Stanford University Hospital Pharmacy, which is nearly identical to that found in the literature.^{30 (link)} In brief, cetuximab (ImClone LLC, Eli Lilly and Company) was provided as a 2 mg mL⁻¹ solution, concentrated, and the pH was adjusted by buffer exchange to a 10 mg mL⁻¹ solution in 50 mmol L⁻¹ potassium phosphate, pH 8.5. IRDye® 800CW NHS ester (LI-COR® Biosciences, Lincoln, NE) was mixed with cetuximab for 2 hours at 20 °C in the dark to enable its conjugation to such, which provided an average molar ratio of 1 : 2.3 cetuximab : IRDye800. After column filtration to remove unconjugated dye and exchanging buffer to phosphate-buffered saline, pH: 7, the final protein concentration adjusted to 2 mg mL⁻¹, the product was sterilized by filtration and placed into single-use vials. After conjugation, the agent was shipped to Stanford University Hospital Pharmacy. During shipping of the immunoconjugate, the temperature was stable at 4 °C. The immunoconjugate was stored at 4 °C until used upon its receipt. The same lot was used for the cohort of animals in the treatment group.